Donor T-Cells take on stubborn CMV in transplant patients
NCT ID NCT02210078
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This phase 2 trial tests whether white blood cells from donors who have been exposed to CMV can treat persistent CMV infections in patients who have had a stem cell transplant. The study includes 49 participants with CMV that has not improved with standard therapy. The goal is to see if these donor immune cells can clear the infection without needing additional treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor cytomegalovirus-specific cytotoxic T-lymphocytes
What this could lead to
If it works, this could offer a new way to control CMV infections in patients who have not responded to standard antiviral drugs after a stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 49 participants, so results may not apply to everyone. The treatment may not work or could cause side effects like graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.